Cholestatic Pruritus Global Market Report 2025

The cholestatic pruritus market size has grown strongly in recent years. It will grow from $19.2 billion in 2024 to $20.28 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth during the historic period can be attributed to the increasing prevalence of skin disorders, higher investments in research and development, growing demand for effective treatments, greater awareness of the condition, and favorable regulatory environments.

The cholestatic pruritus market size is expected to see strong growth in the next few years. It will grow to $24.97 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to the rising elderly population, the increasing prevalence of atopic dermatitis and urticaria, a higher incidence of chronic kidney diseases, and the growing prevalence of conditions associated with pruritus. Key trends during this period include the introduction of new treatment options, partnerships with major companies for cholestatic pruritus research, innovations in treatment modalities, the expansion of healthcare facilities, and technological advancements in care.

The increasing prevalence of liver diseases is expected to drive the growth of the cholestatic pruritus market. Liver diseases encompass a wide range of conditions that impair liver function, including infections, autoimmune disorders, genetic conditions, and damage from toxins, all of which can lead to inflammation, scarring, or even liver failure. Factors such as rising obesity rates, diabetes, alcohol consumption, viral hepatitis, and exposure to environmental toxins contribute to the growing prevalence of liver diseases. Cholestatic pruritus is an important symptom for identifying and managing liver diseases, as it signals impaired bile flow and often prompts further investigation and treatment of underlying liver conditions. For example, in July 2023, the Office for Health Improvement and Disparities, a UK government agency focused on reducing health inequalities, reported that hospital admissions for liver disease in England had risen by 22% in the year ending 2022, from 67,458 to 82,290. The increasing incidence of liver diseases will thus drive the demand for treatments in the cholestatic pruritus market.

Major companies in the cholestatic pruritus market are focusing on developing innovative treatments, such as oral solutions, to better manage symptoms, improve patient compliance, and provide targeted relief by addressing the root causes of bile salt buildup and inflammation. Oral solutions for cholestatic pruritus are liquid medications designed to reduce bile acid accumulation and alleviate severe itching in patients with cholestasis. For instance, in March 2024, Mirum Pharmaceuticals Inc., a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for LIVMARLI (maralixibat) oral solution, which is used to treat cholestatic pruritus in patients aged five and older with progressive familial intrahepatic cholestasis (PFIC). This once-daily, orally administered medication is an ileal bile acid transporter inhibitor and has been designated as a breakthrough therapy for PFIC type 2. LIVMARLI offers a much-needed treatment option for patients with cholestatic pruritus linked to PFIC, particularly for those with the rarest subtypes.

In September 2023, Travere Therapeutics Inc., a U.S.-based biopharmaceutical company, entered into a partnership with Mirum Pharmaceuticals Inc. Through this collaboration, Travere will focus on its core therapeutic areas while Mirum continues to expand its portfolio and develop and commercialize bile acid therapies for rare liver diseases. Mirum Pharmaceuticals is dedicated to advancing treatments for rare liver diseases, including those associated with cholestatic pruritus.

Major players in the cholestatic pruritus market are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Incyte Corporation, Ipsen Pharma, Vanda Pharmaceuticals Inc., Medison Pharma Ltd., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Dipharma Francis S.r.l., Cara Therapeutics Inc., CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Tharimmune Inc., Vifor Fresenius Medical Care Renal Pharma, CymaBay Therapeutics Inc., ICE Pharma Inc., and Aquatic Remedies Private Limited.

North America was the largest region in the cholestatic pruritus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cholestatic pruritus report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cholestatic pruritus market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cholestatic pruritus is a condition characterized by severe itching due to the accumulation of bile acids in the skin, often caused by liver diseases that hinder bile flow. This condition can greatly impact a patient's quality of life and typically requires targeted treatments to alleviate discomfort and address the underlying liver dysfunction.

The primary disease types associated with cholestatic pruritus include primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), intrahepatic cholestasis of pregnancy (ICP), and other related conditions. Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that progressively destroys the bile ducts, causing bile accumulation, liver damage, and possibly cirrhosis. Treatment options for cholestatic pruritus include medications, phototherapy, and other treatments, with administration routes such as oral, topical, and injectable forms. The key end-users for these treatments include hospitals, clinics, ambulatory care centers, and home care settings.

The cholestatic pruritus market research report is one of a series of new reports that provides cholestatic pruritus market statistics, including the cholestatic pruritus industry global market size, regional shares, competitors with the cholestatic pruritus market share, detailed cholestatic pruritus market segments, market trends, and opportunities, and any further data you may need to thrive in the cholestatic pruritus industry. This cholestatic pruritus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cholestatic pruritus market consists of revenues earned by entities by providing services such as diagnosis and screening services, medical consultations and treatment management, patient support programs, and counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The cholestatic pruritus market also includes sales of ursodeoxycholic acid, topical corticosteroids, and opioid antagonists. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.